Vanderbilt Ingram Cancer Center Archives
H. pylori and lung cancer
Aug. 1, 2022—Specific biomarkers for H. pylori — a bacterium that infects the stomach — were associated with increased risk of lung cancer, Vanderbilt researchers have discovered.
Study reveals need for matching targeted therapies with EGFR subtypes
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
VIGH, VICC establish cancer research program in Zambia
Jul. 21, 2022—Vanderbilt University Medical Center and the University of Zambia (UNZA) are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia.
Ginseng intake and mortality
Jun. 20, 2022—Regular ginseng intake, particularly over a long duration, is associated with decreased risk of death from all causes, Vanderbilt researchers discovered in a large epidemiological study.
Breast cancer biomarkers of response
Jun. 16, 2022—Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.
Conquer Cancer awards given to five hematology-oncology fellows
May. 26, 2022—Five Vanderbilt University Medical Center hematology and oncology fellows will receive awards from Conquer Cancer, the ASCO Foundation, during the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, June 3-7.
Clarksville cancer center has new name
May. 19, 2022—The Vanderbilt-affiliated cancer center in Clarksville has a new name: Vanderbilt-Ingram Cancer Center at Tennova Healthcare – Clarksville (VICCTHC).
VICC Scientific Retreat focuses on lung cancer
May. 5, 2022—by Tom Wilemon Speakers at the Vanderbilt-Ingram Cancer Center (VICC) 23rd Annual Scientific Retreat celebrated “Advances in Lung Cancer Research” but noted that too many people with the disease are not benefiting from those achievements. “Lung cancer is our leading cause of cancer mortality. Twenty-nine percent of our total cancers are lung cancer. That’s the...
Studies combine genetic testing, electronic health records to find undiagnosed diseases
Apr. 28, 2022—Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.
Molecular testing across tumor types
Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
Financial impact of prior authorization
Apr. 12, 2022—Prior authorization — health insurer approval of a medical intervention prior to treatment — costs more than $40 million for U.S. academic radiation oncology practices, with questionable value added to patient care.
Clip In 4 the Cure
Mar. 31, 2022—More than 300 riders participated in the inaugural Clip In 4 the Cure, a relay-style, team cycling event that supported cancer initiatives at Vanderbilt-Ingram Cancer Center and Monroe Carell Jr. Children’s Hospital at Vanderbilt.
